Please provide your email address to receive an email when new articles are posted on . Patients who received PD-1 or PD-L1 agents exhibited increased risk for psoriasis. Medical professionals should ...
Older patients have divergent immune phenotypes at baseline that persist during immune checkpoint inhibitor therapy. HealthDay News — Patients with cancer aged 65 years and older receiving immune ...
Use of immune checkpoint inhibitors for cancer was associated with a significant reduction in actinic keratoses in a small study. The effect was greatest in younger patients and those with a history ...
Combination immune checkpoint inhibitor therapy (ICI) with ipilimumab (anti–cytotoxic T-lymphocyte–associated protein 4) + nivolumab (anti–PD-1) in untreated, metastatic melanoma has achieved a ...
MSI-H mCRC patients receiving ICIs had significantly improved OS compared to chemotherapy, with a 63% improvement in survival. MSS patients with high albumin levels or recent antibiotic use also ...
Biomarker analyses provided proof of a mechanism during combination therapy.Yap and his colleagues observed increased CD8+ T cell infiltration and activation in tumors, reduced the regulatory T ...
Three years after enrolling its first patients, a consortium of researchers examining the growing issue of immune-related adverse events due to immune checkpoint inhibitor cancer therapy released a ...
Checkpoint inhibitor-based therapy and ISRT may replace autologous transplant and high-dose chemotherapy in low-risk relapsed cHL, reducing side effects while maintaining EFS outcomes. The CheckMate ...
Use of Ablative Radiotherapy in the Setting of Oligometastatic Disease A retrospective analysis of 3,626 patients treated with ICIs for various malignancies within a single health system was conducted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results